Trial Profile

A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PF 08046054 (Primary)
Indications Advanced breast cancer; Carcinoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; First in man
Sponsors Seagen

Most Recent Events

23 Feb 2026 Planned number of patients changed from 315 to 714.
23 Feb 2026 Planned End Date changed from 8 Apr 2028 to 4 Jan 2029.
23 Feb 2026 Planned primary completion date changed from 9 Apr 2027 to 5 Jan 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com